Up to 40 percent of cancer patients have the kRAS gene, which eliminates the possibility of cancer drugs helping them. The National Cancer Institute has made the elimination of the kRAS effect it’s primary objective, and Tosk has a major initiative underway to make this possible.

Tosk has two additional drug discovery efforts. Consistent with its motto Proven Solutions ImprovedSM. Both are undergoing lead optimization, the process by which a candidate compound is modified to make it into an effective drug.

The first of these is side-effect-reducing compound we call TK-88. TK-88 is intended to reduce or eliminate adverse effects caused by platinum-based drugs, such as cisplatin and carboplatin. These adverse effects can be permanent and include kidney damage, peripheral neuropathy, and hearing loss.

The second research stage targets blocking the cancer gene known as kRAS. Such a drug could be used to make certain cancer therapies effective in patients who do not currently benefit from treatment. It could also be used as a direct cancer therapy for pancreatic and other cancers.